The beauty of real-world data. EHL factor concentrates contribute to declining annual bleed rates

Introduction Optimized haemophilia care with its zero-bleed strategy is critical for patient outcomes. Various therapeutic options are available for treatment individualization, offering higher trough factor levels and a reduction in therapeutic burden. However, does switching from conventional to novel factor concentrates (CFC, FC) with extended half-life (EHL) improve the overall number of bleeds (NBs) in a real-world patient cohort?